Fig. 1A




Fig. 1B




Fig. 2




Fig. 3





Fig. 4



4/21

Fig. 5




* * p < 0.01 c.f week 0

Inventor(s): Phillips et al. Application No: To be Assigned Atty Dkt No: 048501/273281

5/211

÷-1.

Fig. 6



^{*} p < 0.01 cf day 0; same group, ** p < 0.01 Activin A vs FS at relevant time points; # p < 0.05 activin A vs TGF

Inventor(s): Phillips et al. Application No: To be Assigned Atty Dkt No: 048501/273281

Fig. 7





Fig. 8



Title: Compositions and Methods for the Treatment of Disease Inventor(s): Phillips et al.

Application No: To be Assigned Atty Dkt No: 048501/273281

Fig. 9

Fig. 9A




Fig. 9B




Fig. 9C





Fig. 9D



9/.21

Fig. 10

Fig. 10A




Fig. 10B




Fig. 10C






Fig. 10D



Inventor(s): Phillips et al.


Application No: To be Assigned Atty Dkt No: 048501/273281





11/21


Fig. 12



* p < 0.05 c.f control

12/21

Fig. 13




All data non-significant

Inventor(s): Phillips et al. Application No: To be Assigned Atty Dkt No: 048501/273281

13/21


Fig. 14



* p = 0.057, ** p < 0.005 cf with controls


14/21

Fig. 15




15/21

Fig. 16



16/21


Fig. 17



Atty Dkt No: 048501/273281

17/21

Fig. 18



* p< 0.01 cf normals; ** p<0.05 cf normals and 0.01 cf HCV

18/21

Fig. 19





Fig. 20



Inventor(s): Phillips et al.
Application No: To be Assigned
Atty Dkt No: 048501/273281

Fig. 21




Fig. 22

